SCHEMBL13650525

SCHEMBL13650525

Nc1nc(NCCN2CCC2)c2c(n1)C(c1ccccc1)CCC2

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 4/20 0.52
▸ HRH4 Q9H3N8 3/20 0.52
▸ TOP2A P11388 1/20 0.39
▸ ACHE P22303 2/20 0.38
▸ KAT2B Q92831 3/20 0.38
▸ HRH2 P25021 1/20 0.37
▸ BCHE P06276 1/20 0.36
▸ ILK Q13418 1/20 0.36
▸ SIGMAR1 Q99720 1/20 0.35
▸ ACP1 P24666 1/20 0.35
▸ TLR8 Q9NR97 1/20 0.35
▸ TLR7 Q9NYK1 1/20 0.35
▸ CARM1 Q86X55 1/20 0.35
▸ PRMT6 Q96LA8 1/20 0.35
▸ HTR1A P08908 2/20 0.35
▸ DRD2 P14416 2/20 0.35
▸ HTR2A P28223 2/20 0.35
▸ HTR7 P34969 2/20 0.35
▸ HTR6 P50406 2/20 0.35
▸ KDM1A O60341 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13650528 0.98 HRH3 (0.52) HRH3HRH4TOP2AACHEKAT2B
SCHEMBL13650527 0.94 HRH3 (0.50) HRH3HRH4ACHEHRH2BCHE
SCHEMBL13650529 0.92 HRH3 (0.50) HRH3HRH4ACHEHRH2BCHE
SCHEMBL13650530 0.91 HRH3 (0.49) HRH3HRH4ACHEHRH2BCHE
SCHEMBL13650534 0.83 HRH3 (0.49) HRH3HRH4KAT2BHRH2ACP1
SCHEMBL13650647 0.82 HRH3 (0.51) HRH3HRH4ACHEHRH2BCHE
SCHEMBL13650479 0.81 HRH4 (0.50) HRH3HRH4HRH2CARM1PRMT6
SCHEMBL13650569 0.81 HRH3 (0.47) HRH3HRH4ACHEHRH2SIGMAR1
SCHEMBL13650554 0.80 HRH3 (0.46) HRH3HRH4ACHEHRH2BCHE
SCHEMBL13650538 0.80 HRH4 (0.51) HRH3HRH4HRH2HTR1AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436005-B2 Macrocyclic pyrimidine derivatives ABBOTT LABORATORIES (US) 2013-05-07 — — US disclosed
WO-2009123967-A1 5,6,7,8-TETRAHYDROQUINAZOLIN-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H4 RECEPTOR MODULATORS FOR THE TREATMENT OF ASTHMA ABBOTT LABORATORIES (US) 2009-10-08 — — WO disclosed
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2009-10-08 — — US disclosed
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2009-10-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES DPYD, TYMS, TYMP HRH3 3555/4885HRH4 3370/4885TOP2A 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback